Compounds of the formula (1): in which is r u00b9 phenyl optionally substituted by Halogen, Lower alkoxy alkyl, cycloalkyl, Lower Lower Lower alkyl, cyano substituted by Halogen, Hydroxy, alkoxy alkyl substituted by Lower, Lower alkoxy substituted by Halogen or lower IOR is substituted by Hydroxy； or pyridin - 2 -, 3 - or 4 - ILO - optionally substituted by HalogenLower alkyl, cycloalkyl substituted Lower alkyl, cyano, lower by Halogen, alkoxy alkyl substituted by Hydroxy Lower, Lower, Lower alkoxy substituted by Halogen or lower alkoxy substituted by hydroxyl or pyrimidine 2 -, 4 - or 5 - ILO - optionally replaced by Hal u00f3geno Lower, Lower alkyl, cycloalkyl,Lower alkyl substituted by Hydroxy alkyl substituted by Halogen or lower； or is pirazin thiocyanatoacetate optionally substituted by Halogen, Lower alkyl, cycloalkyl alkyl substituted by Halogen, Lower, Lower, Lower alkyl, cyano substituted by Hydroxy is 2.2 - difluorbenzo [； or D [1],3 -] 5 - dioxol ILO or lower alkyl thiazolyl is optionally substituted by Halogen is replaced by Hydrogen or lower alkyl； R u00b2； r u00b3 is Hydrogen or lower alkyl, Amine； Z is a link ch u2082 -, - or - or - or acid Addition Salt of a pharmaceutically suitable for them.The compounds of the formula (1) have a good Affinity with the receptors associated with Trace amines (Taar), especially the TAAR1.The compounds can be used for the treatment of depression, Anxiety Disorders, bipolar disorder, Attention deficit hyperactivity disorder (ADHD), stress disorders, psychotic disorders, Schizophrenia, neurological Diseases u00f3gicas, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease,Epilepsy, Migraine, hypertension, Substance Abuse disorders, Metabolic Disorders, food intake, diabetes, complications of diabetes, obesity, dyslipidemia, disorders of energy consumption and assimilation, disruption and malfunction of The homeostasis of body temperature.The circadian rhythm and Sleep Disorders and cardiovascular diso
